CRSP Stock Price Today (October 2026) — CRISPR Therapeutics AG Analysis & Key Metrics 2026-10-07
CRISPR Therapeutics AG (CRSP) is trading at $52.35, down 3.06% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $87.56 (67.3% upside).
- Volatility is moderate (39.73% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (1041.40% YoY) alongside competitive pressures in the Biotechnology space.
CRSP Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
CRISPR Therapeutics AG - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $3.48B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+67.3% upside potential
Key Investor Questions About CRSP
What investors need to know before buying
Based on current market data, CRSP presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 39.41)
- Fundamentals say: Looking solid (debt and growth supportive)
CRSP's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CRSP investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $783.75M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, CRSP stock traded between $44.12 and $78.48 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 39.73% annualized volatility and β=1.94, the stock exhibits high sensitivity to market moves—making CRSP suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRISPR Therapeutics AG (CRSP) reached $54.23 at the closing of the latest trading day, reflecting a -2.64% change compared to its last close.
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger
CRISPR Therapeutics has seen its share price move around over the years, leaving investors with a mixed track record and a lot of questions about what the current US$55.70 level really reflects. The key issue now is whether that price lines up with the company’s book value or if the market is leaning heavily on more optimistic expectations. Over the past 5 years the stock has fallen 50.2%, which puts the spotlight firmly on whether the balance sheet and book value still underpin today’s...
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Anthropic AI Discovery Gene-Editing Stocks Falling
Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Billionaire Ken Fisher Was Buying These 2 Cathie Wood Stocks
Q2 13F filings show that billionaire Ken Fisher’s Fisher Asset Management opened new positions in CRISPR Therapeutics (NASDAQ: CRSP) and Coinbase Global (NASDAQ: COIN). Fisher’s fund bought 77,960 CRISPR Therapeutics shares valued at about $4.25 million as of June 30. The firm also purchased 9,714 Coinbase shares valued at about $1.42 million. Both stocks were […]
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $59.03 in the latest trading session, marking a +1.2% move from the prior day.
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.
Explore More Analysis for CRSP
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is currently trading at $52.35. The RSI (14-day) is at 39.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $87.56 implies 67.3% upside from current levels. Volatility is moderate at 39.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for CRISPR Therapeutics AG (CRSP): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 2.93. Price-to-Sales is 382.38. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 18 analysts covering CRSP, the consensus price target is $87.56. This represents a 67.3% upside from the current price of $52.35. The range spans from a low target of $44.00 to a high target of $291.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
CRISPR Therapeutics AG (CRSP) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for CRISPR Therapeutics AG (CRSP) investors include: 1. Moderate volatility (39.7% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Elevated short interest (22.6% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is CRISPR Therapeutics AG's (CRSP) current debt and financial health profile: Total debt stands at $783.75M. The debt-to-equity ratio is 0.45x, which is moderate and generally manageable for most companies. The current ratio is 17.85, indicating strong short-term liquidity. The quick ratio is 17.79. The company holds $2.36B in cash and equivalents. Free cash flow is negative at -$215.85M, which could limit the company's ability to manage debt obligations.